Orphan Drug for Pancreatic Cancer Tops SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
5. How Blockchain Technology Will Impact Specialty Pharmacy
The benefits of adopting blockchain technology have not been overlooked by the health care industry and can have a direct and lasting impact on specialty pharmacy. Read more.
4. FDA OKs Treatment for HER2-Negative Breast Cancer with Germline BRCA Mutation
Talazoparib is indicated for patients with known deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. Read more.
3. New Evidence Supports Aspirin Use to Lower Risk of Ovarian Cancer, Liver Cancer
Talazoparib is indicated for patients with known deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. Read more.
2. Survey: MS-Related Cognitive Loss a Top Concern for Patients with MS
Survey participants reported need for better education on how brain atrophy affects multiple sclerosis progression and cognitive loss. Read more.
1. FDA Grants Orphan Status to Targeted Treatment for Pancreatic Cancer
Olaparib (Lynparza, AstraZeneca and Merck), which is being investigated for the treatment of prostate cancer, receives its fourth orphan drug designation from the FDA. Read more.
